Christopher Blewett, MD
Critical Care Medicine · Plano, TXNPI 1255357679
Payments from drug & device makers
Across 394 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- Insmed, Inc.$759
- AstraZeneca$630
- Boehringer Ingelheim$475
- Mallinckrodt Hospital Products Inc.$440
- Baxter Healthcare$287
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,26997%
- Education$2003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 142 | $2,148 |
| Insmed, Inc. | 41 | $759 |
| AstraZeneca | 31 | $630 |
| Boehringer Ingelheim | 23 | $475 |
| Mallinckrodt Hospital Products Inc. | 17 | $440 |
| Baxter Healthcare | 15 | $287 |
| Sanofi | 10 | $275 |
| Johnson & Johnson | 11 | $231 |
| Mylan Specialty L.p. | 12 | $224 |
| Merck | 11 | $220 |
| Grifols USA, LLC | 9 | $191 |
| Advanced Respiratory, Inc | 10 | $158 |
| Electromed, Inc. | 9 | $155 |
| Regeneron Healthcare Solutions, Inc. | 4 | $122 |
| Abiomed | 1 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $102 |
| ANI Pharmaceuticals, Inc. | 4 | $97 |
| AbbVie(2 entities) | 4 | $89 |
| Philips North America LLC | 5 | $81 |
| Viatris Specialty LLC | 3 | $70 |
| Gilead | 3 | $58 |
| Amgen | 3 | $57 |
| Novartis | 3 | $56 |
| United Therapeutics Corporation | 2 | $55 |
| Ambu Inc. | 1 | $45 |
| Mayne Pharma Commercial LLC | 2 | $38 |
| Inari Medical, Inc. | 1 | $36 |
| Boston Scientific | 1 | $31 |
| Shire North American Group Inc | 2 | $29 |
| Liquidia Technologies, Inc. | 1 | $29 |
| Pfizer | 1 | $27 |
| Ceribell, Inc. | 2 | $25 |
| Vapotherm Inc | 1 | $24 |
| Penumbra, Inc. | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$112
How this compares
$7,469 in reported general payments places this provider in the 85th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 45 | $609,212 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 12 | $184,066 |
| Ambrisentan | 12 | $34,200 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $32,786 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $22,933 |
| Spiriva RespimatTiotropium Bromide | 29 | $19,915 |
| EliquisApixaban | 12 | $11,539 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,032 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $7,481 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $3,617 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,887 |
| Esomeprazole Magnesium | 22 | $1,222 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $336 |
| Rifampin | 12 | $203 |
| Gabapentin | 11 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $475 | $629,12774 claims |
| Insmed, Inc.Arikayce | $759 | $184,06612 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $2,148 | $59,335114 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $630 | $15,51344 claims |
| PfizerEliquis | $27 | $11,53912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in Plano
- Steven DavidoffPlano$364K
- James WilsonPlano$55K
- David MyersPlano$42K
- Tayler LongPlano$13K
- Cynthia ZamoraSan Antonio$6.4M
- Rishi RajLubbock$1.9M
- Carlo HatemEl Paso$1.6M
- Deepa GoturHouston$1.1M
- Matt KhoshnevisHouston$759K
- Sean GilbeyAustin$723K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.